_256_384.jpg)
News | May 14, 2025
Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
The company has posted net profit of Rs. 82.62 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 77.60 crores for the Financial Year ended March 31, 2025
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Scores highest PAT of Rs. 118 crore in FY25
This marks yet another milestone in our series of successful audits over the past year
The company has posted net profit of Rs. 55.36 crores for the Financial Year ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
